Viewing Study NCT05219318


Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2025-12-26 @ 4:06 AM
Study NCT ID: NCT05219318
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-04
First Post: 2022-01-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Sponsor: University Hospital, Bordeaux
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module